Supernus, Inc. (NASDAQ: SUPN) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Supernus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.04, Supernus, Inc. trades at 8.0x trailing earnings and 4.4x sales, with an EV/EBITDA of 11.0. Over the last twelve months it generated about $1.4B of revenue and $758M of net income. It runs a gross margin of 85.2%, an operating margin of 43.7% and a net margin of 32.8%. It shows return on equity of -352.9%, return on invested capital of 95.4% and a free cash flow yield of 0.5%. On the balance sheet: a debt-to-equity ratio of -8.35 and a current ratio of 0.61. Over the past 52 weeks the share price ranged from $25.92 to $43.20, with a beta of 0.52.
Supernus, Inc. pays a dividend yielding 27.93%.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.